Federal grants to Enyx Therapeutics LLC
Enyx Therapeutics LLC in New York, New York received $2.1 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Alcohol Research Programs, with $1.3 million. In fiscal 2025 it was awarded $1.3 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$2.1 million
- Awards4
- Awarded in FY 2025$1.3 million
- Largest award$1.3 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 1 | $300,000 |
| FY 2023 | 0 | $0 |
| FY 2024 | 2 | $571,638 |
| FY 2025 | 1 | $1.3 million |
Programs that fund Enyx Therapeutics LLC
| Program | Awards | Amount |
|---|---|---|
| Alcohol Research Programs | 1 | $1.3 million |
| Allergy and Infectious Diseases Research | 2 | $575,737 |
| Human Genome Research | 1 | $295,901 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $2.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Gene therapy to treat ethanol-induced osteoporosis associated with aldehyde dehydrogenase 2 deficiency in post-menopausal east asian women - abstract. Enyx therapeutics, LLC, is an early-stage biotechnology company focused on using in vivo gene therapy technologies to treat hereditary disorders of u | Alcohol Research Programs | August 27, 2025 | $1.3 million |
| Anti-eosinophil gene therapy for eosinophilic esophagitis - abstract. Eosinophilic esophagitis (EOE), a chronic upper gastrointestinal disabling disorder affecting children and adults, is characterized by eosinophil esophageal inflammation, progressive disordering of esophageal architecture, esophag | Allergy and Infectious Diseases Research | May 5, 2022 | $300,000 |
| Gene therapy-mediated angiogenesis to enhance survival of transplanted fat - abstract. Autologous fat grafts are widely used for soft tissue reconstruction of congenital deformations, defects caused by traumatic wounds, oncologic surgery, and improving the form and function of skin grafts, scar cont | Human Genome Research | April 25, 2024 | $295,901 |
| Safety of aav-mediated C1 esterase inhibitor gene therapy for hereditary angioedema - abstract. Hereditary angioedema (HAE) is a potentially life-threatening autosomal dominant disorder characterized by recurrent swelling of cutaneous tissues, gastrointestinal and respiratory tracts. Almost all case | Allergy and Infectious Diseases Research | March 15, 2024 | $275,737 |
Questions people ask
How much federal grant money does Enyx Therapeutics LLC get?
$2.1 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Enyx Therapeutics LLC the most?
The Department of Health and Human Services, with $2.1 million in 4 awards.
What is Enyx Therapeutics LLC's largest federal grant?
$1.3 million under Alcohol Research Programs, with its first action in the period on August 27, 2025. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Enyx Therapeutics LLC?
Its largest are Alcohol Research Programs, Allergy and Infectious Diseases Research and Human Genome Research.
Other grant recipients in New York
- Metropolitan Transportation Authority
- New York City Housing Authority
- Gateway Development Commission
- The Trustees of Columbia University in the City of New York
- Icahn School of Medicine at Mount Sinai
- New York University
- Inclusiv, Inc
- International Rescue Committee, Inc.
Largest federal grant recipients in New York · Federal grants in New York